rucaparib,abiraterone,enzalutamide
pfizer,astellas,clovis oncology
['#gu,(-#gui),(-#gunagratinib),(-#guard),(-#gut)']
no significant difference in rpfs for pts with atm mutations. 3/4 of pts crossed over. os immature. results published in #gu23 
CME experts Sara Fagerlie, PhD, CHCP & Mindy Tanzola, PhD have joined forces at Front Row to share the latest heme/onc news with  clinicians and educators